Viessmann and Armira completed the acquisition of a minority stake in PharOS.

Viessmann, a diversified business group, and Armira, an investment holding company, completed the acquisition of a minority stake in PharOS, a pharmaceutical company that develops, manufactures and supplies generics and value-added products. Financial terms were not disclosed. “Our entrepreneurial activities aim to strategically elevate essential areas that are crucial for the well-being of future generations. Generic medicines make up the backbone of affordable global pharmaceutical care. With our investment in PharOS we want to contribute to a more stable, independent and resilient European supply of affordable and effective treatments for life-threatening diseases," Max Viessmann, Viessmann CEO.